Author of

• 10874

  +

  P1.13 - Poster Session 1 - SCLC (ID 200)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10877

    +

    P1.13-003 - Impact of pre-treatment serum lactate dehydrogenase on survival in patients with small cell lung cancer. (ID 1295)

    09:30 - 09:30  |  Author(s): R. Woodman
    • Abstract

    Background
    Serum lactate dehydrogenase (sLDH) is a prognostic factor in small cell lung cancer (SCLC). The aim of this study was to evaluate the impact of pre-treatment levels on survival in a contemporary patient population with limited disease (LD) and extensive disease (ED).

    Methods
    SCLC patients were identified by searching the hospital cancer registry from 1999 to 2009. Patient characteristics, sLDH, management and outcomes were collated by reviewing clinical records. A sLDH result < 230 was designated normal and a result >230 was designated elevated in line with our institutional reference range. Survival analysis was performed using stata software using cox regression.

    Results
    168 patients were diagnosed with SCLC, 103 males and 65 females. Median patient age was 71 years. Pre-treatment sLDH was available for 128 patients. An elevated sLDH was associated with worse survival with Hazard Ratio (HR) 2.17 (95% CI 1.46-3.20, p-value <0.001). Elevated sLDH remained a significant independent poor prognostic factor in a multivariate model when adjusted for age, sex, treatment and stage. In LD patients 52.6% had an elevated sLDH and median overall survival (MOS) was significantly worse in patients with elevated sLDH compared with normal sLDH, 7.97 months versus 16.50 months (HR 2.1, 95% CI 1.07-4.32, p-value = 0.032). In ED patients 69.4% had an elevated sLDH and MOS was also significantly worse in patients with elevated sLDH compared with normal sLDH, 5.22 months versus 8.23 months (HR 1.8, 95% CI 1.1-2.9, p-value = 0.019). Figure 1Figure 2

    Conclusion
    This study confirms the prognostic significance of sLDH. LD patients with an elevated sLDH had a MOS which was similar to ED patients with a normal sLDH. Further studies to determine the biology of this subgroup of poor prognostic patients will be important to tailor therapeutic strategies.